Search
Search Results
##search.searchResults.foundPlural##
-
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2724PDF: 973HTML: 5494 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1640PDF: 787HTML: 137 -
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
896PDF: 1179HTML: 88 -
IMMUNOLOGICAL EVOLUTION OF A COHORT OF HIV-2 INFECTED PATIENTS: PECULIARITIES OF AN UNDERESTIMATED INFECTION HIV-2 INFECTED PATIENTS PECULIARITIES
923PDF: 580HTML: 212 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3370PDF: 1442HTML: 63 -
REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy
1474PDF: 557HTML: 167 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1310PDF: 1264HTML: 78 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1594PDF: 1114HTML: 227 -
CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
1224PDF: 586HTML: 3051 -
Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report Liver involvement in familial Mediterranean fever
1194PDF: 868HTML: 277 -
Correlation to FVIII:C in two thrombin generation tests: TGA-CAT and INNOVANCE ETP
2167PDF: 751HTML: 844Figure 2: 197Figure 1: 151 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1283HTML: 362PDF: 785 -
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2508PDF: 833HTML: 17439Fig1 Caligaris: 142Fig.2 Caliga: 176 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
3974PDF: 1513HTML: 814 -
ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
1640PDF: 776HTML: 921cover letter: 246 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1104PDF: 996HTML: 171 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2057PDF: 1734HTML: 118 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1531PDF: 1126HTML: 181 -
ENDOTHELIAL BIOMARKERS IN PATIENTS RECOVERED FROM COVID-19 ONE YEAR AFTER HOSPITAL DISCHARGE: A CROSS-SECTIONAL STUDY Endothelial biomarkers in COVID-19 recoverers one year after hospital discharge.
1174PDF: 698HTML: 286 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
896PDF: 483HTML: 169 -
CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
1599PDF: 697HTML: 2326 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7186PDF: 2346HTML: 1700Table 1.: 183Table 2.: 199Table 3.: 179Table 4.: 178 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2050PDF: 1918HTML: 139 -
-
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3808PDF: 1429HTML: 9169Untitled: 255Untitled: 158Untitled: 148Untitled: 143Untitled: 162Untitled: 315 -
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
2530PDF: 1028HTML: 96







